Flesinoxan (DU-29,373) is a potent and selective 5-HT1A receptor partial/near-full agonist of the phenylpiperazine class.[1][2][3] Originally developed as a potential antihypertensive drug,[1][2][4] flesinoxan was later found to possess antidepressant and anxiolytic effects in animal tests.[5][6] As a result, it was investigated in several small human pilot studies for the treatment of major depressive disorder, and was found to have robust effectiveness and very good tolerability.[7][8] However, due to "management decisions", the development of flesinoxan was stopped and it was not pursued any further.[9]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C22H26FN3O4 |
Molar mass | 415.465 g·mol−1 |
3D model (JSmol) |
|
| |
|
In patients, flesinoxan enhances REM sleep latency, decreases body temperature, and increases ACTH, cortisol, prolactin, and growth hormone secretion.[2][8]